The Clinical Effect of Moxifen Tablets Combined with Medroxyprogesterone Acetate Injection on Patients with Endometriosis

Abstract

To explore the clinical effect of moxifen tablets combined with medroxyprogesterone acetate injection on patients with endometriosis. Methods: 90 patients with endometriosis from August 2018 to March 2019 were randomly divided into control group and observation group, with 45 cases in each group. The control group was treated with moxifene tablets and the observation group with medroxyprogesterone acetate. The changes of serum sex hormone, P, CA125 levels, adverse reactions and therapeutic effects were compared between the two groups.Result: Before treatment, there was no significant difference in serum sex hormone and P, CA125 levels between the two groups (P > 0.05); after treatment, the indexes of the two groups were reduced, and the LH, E₂, FSH, CA125 and P water in the observation group were lower than those in the control group (P < 0.05); the curative effect of the observation group was significantly better than that in the control group (P < 0.05); the incidence of adverse reactions in the observation group was lower than that in the control group (P < 0.05). Conclusion: Moxifene combined with medroxyprogesterone acetate has a significant therapeutic effect on endometriosis. It can significantly reduce the level of serum sex hormone. The incidence of adverse reactions is low and the treatment safety is high. It is worth popularizing.